AB Science Holds the Clinical Studies of Masitinib Globally

 AB Science Holds the Clinical Studies of Masitinib Globally

AB Science Holds the Clinical Studies of Masitinib Globally

Shots:

  • The company holds the inclusion and initiation of treatment in ongoing 3 studies i.e P-III in mastocytosis (AB15003), P-III study in AML (AB19001) & P-II in COVID (AB20001) for masitinib, until the investigation of safety issue is completed
  • The decision follows discussions with the French regulatory authorities (ANSM) and other regulatory agencies. The company also work closely with them to carry out the necessary additional analyzes
  • AB Science has filed or will submit without delay a request for temporary discontinuation of the ongoing studies in all countries

Click here to­ read full press release/ article | Ref: AB Science | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post